Top Banner
Neoplasia
64

Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Dec 19, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Neoplasia

Page 2: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Nomenclature

• Benign: -oma (adenoma, fibroma)

• Malignant:

– carcinoma (epithelial origin)

(adenocarcinoma)

– sarcoma (mesenchymal origin)

(fibrosarcoma)

Page 3: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

AdenomaAdenoma

Page 4: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

AdenomaAdenoma

Page 5: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

PapillomaPapilloma

Page 6: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

PolypPolyp

Page 7: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Non-Neoplastic Proliferation:

Controlled & Reversible• Hypertrophy – Size

• Hyperplasia – Number

• Metaplasia – Change

• Dysplasia – Disordered

Page 8: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Neoplastic Proliferation:

Uncontrolled & Irreversible

• Benign– Localized, non-invasive.

• Malignant (Cancer)– Spreading, Invasive.

Page 9: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Dysplasia

• Loss of architectural organization and orientation and a loss of cell uniformity in tissue.

• Dysplasia is a non-neoplastic proliferation.

• Dysplasia may or may not progress to cancer.

Page 10: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here, there is normal cervical squamous epithelium at the left, but dysplastic squamous epithelium at the right. Dysplasia is a disordered growth of epithelium, but still confined to the epithelium. Dysplasia is still reversible.

Page 11: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• At high magnification, the normal cervical squamous epithelium at the left merges into the dysplastic squamous epithelium at the right in which the cells are more disorderly and have darker nuclei with more irregular outlines.

Page 12: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here is a cervical Pap smear in which dysplastic cells are present that have much larger and darker nuclei than the normal squamous cells with small nuclei and large amounts of cytoplasm.

Page 13: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• When the entire epithelium is dysplastic and no normal epithelial cells are present, then the process has gone beyond dysplasia and is now neoplasia. If the basement membrane is still intact, as shown here, then the process is called "carcinoma in situ" because the carcinoma is still confined to the epithelium.

Page 14: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Differentiation

• Rate of growth

• Invasion

• Metastasis

Page 15: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Slow growing,• Enapsulated, • Non-invasive • Do not

metastasize, • well differentiated, • suffix “oma” eg.

Fibroma.

• Fast growing,

• Not capsulated,

• Invasive & Infiltrate

• Metastasize.

• poorly differentiated,

• Suffix “Carcinoma” or “Sarcoma”

Benign Malignant

Page 16: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)
Page 17: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)
Page 18: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

ANAPLASIA

Page 19: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Pleomorphism: variation in size and shape

Page 20: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)
Page 21: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Abnormal nuclear morphology: hyperchormatic (abundant DNA), increased N:C ratio (normal 1:5)

Page 22: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)
Page 23: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Mitoses: increased

Page 24: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here are three abnormal mitoses. Mitoses by themselves are not indicators of malignancy. However, abnormal mitoses are highly indicative of malignancy. The marked pleomorphism and hyperchromatism of surrounding cells also favors malignancy.

Page 25: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Tripolar mitotic figure (abnormal)

Page 26: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)
Page 27: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This sarcoma has many mitoses. A very large abnormal mitotic figure is seen at the right.

Page 28: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Loss of polarity

Page 29: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Of course, neoplasms can be benign as well as malignant, though it is not always easy to tell how a neoplasm will act. Here is a benign lipoma on the serosal surface of the small intestine. It has the characteristics of a benign neoplasm: it is well circumscribed, slow growing, non-invasive, and closely resembles the tissue of origin (fat).

Page 30: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• At low power magnification, a lipoma of the stomach is seen to be well demarcated from the mucosa at the lower center-right. This neoplasm is so well-differentiated that, except for its appearance as a localized mass, it is impossible to tell from normal adipose tissue.

Page 31: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here is the lipoma at high magnification. This is a good example of how a benign neoplasm mimics the tissue of origin. These neoplastic adipocytes are indistinguishable from normal adipocytes.

Page 32: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This large mass lesion is a liposarcoma. This one is yellowish, like adipose tissue, and is well-differentiated.

Page 33: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This liposarcoma has enough differentiation to determine the cell of origin (adipocyte), but there is still significant pleomorphism of these neoplastic cells (lipoblasts).

Page 34: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Benign neoplasms can be multiple, as is shown in this uterus opened anteriorly to reveal leiomyomas of varying size, but all benign and well-circumscribed firm white masses.

Page 35: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• The microscopic appearance of a leiomyoma indicates that the cells do not vary greatly in size and shape and closely resemble normal smooth muscle cells.

Page 36: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here is a small hepatic adenoma, an uncommon benign neoplasm, but one that shows how well-demarcated a benign neoplasm is. It also illustrates how function of the normal tissue can be maintained, because this adenoma is making bile pigment, giving it a green color with formalin fixation.

Page 37: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Hepatic Adenoma

Normal Normal AdenomaAdenoma

Page 38: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This squamous cell carcinoma demonstrates enough differentiation to tell that the cells are of squamous origin. The cells are pink and polygonal in shape with intercellular bridges (seen as desmosomes or "tight junctions" by electron microscopy). However, the neoplastic cells show pleomorphism, with hyperchromatic nuclei. A mitotic figure is present near the center.

Page 39: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This neoplasm is so poorly differentiated that it is difficult to tell what the cell of origin is. It is probably a carcinoma because of the polygonal nature of the cells. Note that nucleoli are numerous and large in this neoplasm.

Page 40: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

INVASION

Page 41: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Malignant neoplasms are characterized by their tendency to invade surrounding tissues. Here, the tan tissue of a lung cancer is seen to be spreading along the bronchi into the surrounding lung. The dark round areas are lymph nodes also involved by the neoplasm.

Page 42: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This is a squamous cell carcinoma of the lung. It is a bulky mass that extends into surrounding lung parenchyma.

Page 43: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

METASTASIS

Page 44: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Metastatic Adenocarcinoma

Page 45: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• This is an example of metastases to the liver. A primary neoplasm is more likely to appear within an organ as a solitary mass. The presence of metastases are the best indication that a neoplasm is malignant. The original clone of cells that developed into a neoplasm may not have had the ability to metastasize, but continued proliferation of the neoplastic cells and acquisition of more genetic mutations within the neoplastic cells can give them the ability to metastasize.

Page 46: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Microscopically, metastatic adenocarcinoma is seen in a lymph node here. It is common for carcinomas to metastasize to lymph nodes. The first nodes involved are those receiving lymphatic drainage from the site of the primary neoplasm.

Page 47: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Neoplasms can spread by seeding within body cavities such as the pleural cavity or peritoneal cavity. This pattern of spread is more typical for carcinomas than other neoplasms. Note the multitude of small tan tumor nodules seen over the peritoneal surface of the mesentery shown here.

Page 48: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Epidemiology

Page 49: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Multiple adenomatous polyps (tubulovillous adenomas) of the cecum are seen here in a case of familial adenomatous polyposis, a genetic syndrome in which an abnormal genetic mutation leads to development of multiple neoplasms in the colon. The genetic abnormalities present in neoplasms can be inherited or acquired.

Page 50: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Carcinogens

• Chemical

• Radiation

• Viral

• Bacterial

Page 51: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Chemical agents

• Many chemical carcinogens are related to lifestyle– Polycyclic Hydrocarbons– Aromatic amines – Nitroseamines

– Aflatoxin B1

Page 52: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Radiation

– Nuclear radiation

– Neck radiation

– UV light

Page 53: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Viruses

– Human T-Cell Leukemia Virus Type 1– Human papillomavirus (HPV)– Eptein-Barr virus (EBV)– Human Herpes Virus 8– Hepatitis B,C virus (HBV,HCV)

Page 54: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Bacteria

– Helicobacter pylori

Page 55: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Clinical ManifestationsParaneoplastic Syndromes

• Disruption of tissue integrity

• Compression of adjacent structures

• Pain

• Wasting (Cachexia)

• Fatigue

• Anemia

• Infection

Page 56: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Clinical Features of Malignancy

• Paraneoplastic Syndromes– 10-15% of cancer patients– Symptoms that can’t be explained by spread

of the tumor or by indigenous hormones

• Endocrinopathies (SIADH, Hypercalcemia)• Vascular and hematologic changes (thrombosis)

Page 57: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• A paraneoplastic syndrome occurs when a neoplasm elaborates a substance that results in an effect that is not directly related to growth, invasion, or metastasis of the tumor itself.

• Sometimes the appearance of the paraneoplastic syndrome may precede diagnosis of the neoplasm and may give a clue to its presence.

Page 58: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

CACHEXIA

• Loss of fat and muscle, weakness, anemia, anorexia

• Anorexia due to altered sense of taste, central control of appetite

• Increased basal metabolic rate

• TNF- and IL-1

Page 59: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Screening and Diagnosis

• Radiographic exams

• Lab tests

• Biopsy

• Grading and staging

Page 60: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

• Here is an example of c-erb-B2 (HER2) positivity of the neoplastic cells in a breast carcinoma. This oncogene acts via reduplication of the normal proto-oncogene hundreds of times, leading to production of a protein product that drives unregulated cell growth. This is detected here by immunohistochemical staining, with the brown reaction product concentrated in a perimembranous pattern around the neoplastic cells.

Page 61: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Staging

• The most common systems for staging employs the TNM classification. A "T" score is based upon the size and/or extent of invasion. The "N" score indicates the extent of lymph node involvement. The "M" score indicates whether distant metastases are present. Staging forms have been devised for each organ or site that a malignant neoplasm can occur, and the criteria are listed on the form. The forms are filled out using clinical and pathologic criteria and aid in determination of therapy, estimating the prognosis, and developing statistics useful for determining outcomes.

Page 62: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Grading

• Grading schema are based upon the microscopic appearance of a neoplasm with H&E staining. In general, a higher grade means that there is a lesser degree of differentiation and the worse the biologic behavior of a malignant neoplasm will be. A well-differentiated neoplasm is composed of cells that closely resemble the cell of origin, while poorly differentiated neoplasms have cells that are difficult to recognize as to their cell of origin. Grading schema have been devised for many types of neoplasms, mainly carcinomas. Most grading systems have three or four grades (designated with numbers or roman numerals).

Page 63: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Grading and Staging

• Grade – Microscopic (degree of differentiation)

• Stage – Pathologic and clinical findings describing the extend of disease

• AJCC Stage – I-IV• Based on T – size and invasiveness of tumor, N –

presence or absence of nodal metastases, M – presence or absence of distant metastases

• Stage is a stronger predictor of prognosis than grade

Page 64: Neoplasia. Nomenclature Benign: -oma (adenoma, fibroma) Malignant: –carcinoma (epithelial origin) (adenocarcinoma) –sarcoma (mesenchymal origin) (fibrosarcoma)

Grading of Malignant Neoplasms

Grade Definition

I Well differentiated

II Moderately differentiated

III Poorly differentiated

IV Nearly anaplastic